

Silvia Monticone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899709/publications.pdf>

Version: 2024-02-01

98
papers

5,590
citations

94433

37
h-index

82547

72
g-index

99
all docs

99
docs citations

99
times ranked

3627
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary aldosteronism in pregnancy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 39-48.	5.7	9
2	Response to Letter to the Editor from Rossi and Rossitto: "Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e896-e897.	3.6	0
3	Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19. <i>American Journal of Cardiology</i> , 2022, , .	1.6	3
4	Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage. <i>Hypertension</i> , 2022, 79, 863-873.	2.7	27
5	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature. <i>Translational Research</i> , 2022, , .	5.0	8
6	Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles. <i>Vascular Pharmacology</i> , 2022, 145, 106999.	2.1	11
7	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. <i>Journal of Personalized Medicine</i> , 2022, 12, 990.	2.5	2
8	Adrenal Venous Sampling"Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1400-e1407.	3.6	25
9	Quality of life in primary aldosteronism: A prospective observational study. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13419.	3.4	7
10	Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinson's Disease. <i>Biomedicines</i> , 2021, 9, 230.	3.2	12
11	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. <i>Frontiers in Pharmacology</i> , 2021, 12, 668843.	3.5	0
12	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3655-e3664.	3.6	16
13	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. <i>Hypertension</i> , 2021, 78, 1595-1604.	2.7	10
14	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021, 78, 726-737.	2.7	14
15	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1708-1716.	3.6	16
16	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e282-e289.	3.6	29
17	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. <i>Hypertension</i> , 2020, 75, 163-172.	2.7	33
18	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study. , 2020, 2, e0220.		2

#	ARTICLE	IF	CITATIONS
19	Antecedent Administration of Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVIDâ€19 Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e017364.	3.7	29
20	An extracellular vesicle epitope profile is associated with acute myocardial infarction. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9945-9957.	3.6	27
21	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â€“. <i>Journal of Hypertension</i> , 2020, 38, 1919-1928.	0.5	151
22	Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?. <i>Hormone and Metabolic Research</i> , 2020, 52, 366-372.	1.5	14
23	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3706-e3717.	3.6	47
24	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. <i>Hypertension</i> , 2020, 75, 1025-1033.	2.7	60
25	Familial Hyperaldosteronism. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 79-93.	0.1	1
26	The spectrum of low-renin hypertension. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101399.	4.7	17
27	Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism. <i>Hormones and Cancer</i> , 2020, 11, 52-62.	4.9	8
28	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. <i>International Journal of Cardiology: Hypertension</i> , 2020, 5, 100029.	2.2	69
29	Primary Aldosteronism in the Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2320-e2326.	3.6	12
30	Renal damage in primary aldosteronism. <i>Journal of Hypertension</i> , 2020, 38, 3-12.	0.5	63
31	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. <i>European Journal of Endocrinology</i> , 2020, 183, 657-667.	3.7	8
32	Gender differences in acute coronary syndromes patterns during the COVID-19 outbreak. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 506-513.	0.5	1
33	Evaluation of Unattended Automated Office, Conventional Office and Ambulatory Blood Pressure Measurements and Their Correlation with Target Organ Damage in an Outpatient Population of Hypertensives: Study Design and Methodological Aspects. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 493-499.	2.2	1
34	Primary Aldosteronism and Obstructive Sleep Apnea. <i>Hypertension</i> , 2019, 74, 1532-1540.	2.7	45
35	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 359-367.	2.7	23
36	Comparison of Automated Office Blood Pressure With Office and Out-Off-Office Measurement Techniques. <i>Hypertension</i> , 2019, 73, 481-490.	2.7	57

#	ARTICLE	IF	CITATIONS
37	Genetics of Familial Hyperaldosteronism. , 2019, , 623-630.		1
38	Primary aldosteronism in the primary care setting. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 155-159.	2.3	12
39	GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. European Journal of Endocrinology, 2018, 178, R101-R111.	3.7	46
40	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
41	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 41-50.	11.4	582
42	Diagnostic approach to low-renin hypertension. Clinical Endocrinology, 2018, 89, 385-396.	2.4	32
43	Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 167-176.	2.2	20
44	Pharmacological Treatment of Arterial Hypertension in Children and Adolescents. Hypertension, 2018, 72, 306-313.	2.7	32
45	Regulation of Aldosterone Production. , 2018, , 429-449.		1
46	Diagnosis of primary aldosteronism in the hypertension specialist centers in Italy: a national survey. Journal of Human Hypertension, 2018, 32, 745-751.	2.2	7
47	Liddle Syndrome: Review of the Literature and Description of a New Case. International Journal of Molecular Sciences, 2018, 19, 812.	4.1	69
48	Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. International Journal of Molecular Sciences, 2018, 19, 1675.	4.1	5
49	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. Journal of the American College of Cardiology, 2017, 69, 1811-1820.	2.8	520
50	Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 187-192.	2.2	0
51	The SPARTACUS Trial: Controversies and Unresolved Issues. Hormone and Metabolic Research, 2017, 49, 936-942.	1.5	33
52	Is Primary Aldosteronism Still Largely Unrecognized?. Hormone and Metabolic Research, 2017, 49, 908-914.	1.5	50
53	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. Journal of the Endocrine Society, 2017, 1, 401-406.	0.2	3
54	Is There a Role for Genomics in the Management of Hypertension?. International Journal of Molecular Sciences, 2017, 18, 1131.	4.1	40

#	ARTICLE	IF	CITATIONS
55	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. International Journal of Molecular Sciences, 2017, 18, 848.	4.1	40
56	Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Frontiers in Cell and Developmental Biology, 2016, 4, 83.	3.7	226
57	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. Journal of Hypertension, 2016, 34, 920-927.	0.5	61
58	Guidelines for primary aldosteronism. Journal of Hypertension, 2016, 34, 2253-2257.	0.5	134
59	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 203-208.	2.2	3
60	Association Between Lifestyle and Systemic Arterial Hypertension in Young Adults: A National, Survey-Based, Cross-Sectional Study. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 31-40.	2.2	28
61	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	2.7	63
62	Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 73-82.	2.2	0
63	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E114-E118.	3.6	53
64	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Molecular and Cellular Endocrinology, 2015, 411, 146-154.	3.2	115
65	<i>KCNJ5</i> Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism. Hypertension, 2015, 65, 507-509.	2.7	34
66	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes and Endocrinology, 2015, 3, 296-303.	11.4	134
67	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Molecular and Cellular Endocrinology, 2015, 399, 311-320.	3.2	45
68	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
69	Diabetes in Hyperaldosteronism. Frontiers in Diabetes, 2014, , 34-43.	0.4	0
70	Aldosterone Suppression on Contralateral Adrenal During Adrenal Vein Sampling Does Not Predict Blood Pressure Response After Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4158-4166.	3.6	62
71	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
72	Familial Hyperaldosteronism Type I. , 2014, , 75-86.		0

#	ARTICLE	IF	CITATIONS
73	Familial Hyperaldosteronism Type III. , 2014, , 99-108.		0
74	A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1861-E1865.	3.6	86
75	Role of KCNJ5 in familial and sporadic primary aldosteronism. Nature Reviews Endocrinology, 2013, 9, 104-112.	9.6	101
76	Primary Aldosteronism: Progress in Diagnosis, Therapy, and Genetics. , 2013, , 3-32.		1
77	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4826-4833.	3.6	348
78	Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism. Current Hypertension Reviews, 2013, 9, 156-165.	0.9	9
79	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	2.7	176
80	Visinin-Like 1 Is Upregulated in Aldosterone-Producing Adenomas With <i>KCNJ5</i> Mutations and Protects From Calcium-Induced Apoptosis. Hypertension, 2012, 59, 833-839.	2.7	64
81	High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. Nephrology Dialysis Transplantation, 2012, 27, 1793-1800.	0.7	63
82	Effect of <i>KCNJ5</i> Mutations on Gene Expression in Aldosterone-Producing Adenomas and Adrenocortical Cells. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1567-E1572.	3.6	130
83	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 881-889.	3.6	105
84	Effect of Adrenocorticotrophic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2012, 59, 840-846.	2.7	87
85	Atypical secondary hypertension due to mid-aortic syndrome. European Heart Journal, 2012, 33, 2248-2248.	2.2	3
86	Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocrine Journal, 2012, 59, 497-502.	1.6	24
87	Adrenal disorders in pregnancy. Nature Reviews Endocrinology, 2012, 8, 668-678.	9.6	37
88	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
89	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Molecular and Cellular Endocrinology, 2012, 355, 162-168.	3.2	18
90	Genomic and Non-genomic Effects of Aldosterone. Current Signal Transduction Therapy, 2012, 7, 132-141.	0.5	16

#	ARTICLE	IF	CITATIONS
91	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. Journal of Hypertension, 2011, 29, 1773-1777.	0.5	50
92	Diagnosis and treatment of primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 3-9.	5.7	30
93	Is Familial Hyperaldosteronism Underdiagnosed in Hypertensive Children?. Hypertension, 2011, 57, 1053-1055.	2.7	15
94	Rapid Cortisol Assay Increases the Success of Adrenal Vein Sampling. American Journal of Hypertension, 2011, 24, 1265-1265.	2.0	5
95	Prevalence and Characteristics of Familial Hyperaldosteronism. Hypertension, 2011, 58, 797-803.	2.7	128
96	Evaluation of primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 188-193.	2.3	21
97	Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro. Hypertension, 2010, 55, 1468-1475.	2.7	43
98	Controversies on the Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 173-178.	2.2	0